A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
Katherine LaVigneRoisin E OʼCearbhaill

Abstract

Hypersensitivity with repeated exposure to platinum agents is common and can preclude continued treatment, even in patients with disease that remains platinum sensitive. We sought to compare the effects of prophylactic, extended carboplatin infusion versus standard infusion on the rate of carboplatin hypersensitivity reactions (HSRs) in women with recurrent ovarian cancer. This was a single-institution, randomized, nonblinded trial comparing a graded, 3-hour extended infusion of carboplatin with a standard 30-minute infusion in patients with recurrent ovarian cancer who were enrolled from January 2011 to April 2015. The study was designed to detect a decrease in the HSR rate from 20% (standard infusion) to 5% (extended infusion) assuming a type 1 error of 10% and power of 80% using a 1-sided test. Of 146 enrolled patients, 114 were evaluable. Fifteen (13%) had an HSR-11% (6/56) in the extended-infusion and 16% (9/58) in the standard-infusion groups (P = 0.582). Planned treatment completion was achieved in 50 (89%) of 56 patients and 49 (84%) of 58 patients, respectively. Of 25 patients who received single-agent carboplatin, 8 (32%) had an HSR (53% of all patients who had an HSR [8/15]). Of 23 patients who received carboplatin w...Continue Reading

References

Mar 11, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M MarkmanJ L Lewis
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J S MorganM D Mason
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M MarkmanJ Belinson
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Don S DizonDavid R Spriggs
Jun 27, 2006·Gynecologic Oncology·Marisa NavoJudith A Smith
May 27, 2008·The Journal of Allergy and Clinical Immunology·Mariana C CastellsUrsula A Matulonis
Aug 30, 2008·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·A GadducciA R Genazzani
May 2, 2009·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·H KoshibaH Honjo
Jul 16, 2014·The Journal of Allergy and Clinical Immunology. in Practice·Aleena BanerjiAidan A Long
Jul 2, 2015·Current Allergy and Asthma Reports·Joana Caiado, Mariana Castells
Nov 20, 2016·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Katarzyna J JerzakHelen J Mackay
Apr 16, 2017·Gynecologic Oncology·David M O'MalleyJohn L Hays

❮ Previous
Next ❯

Citations

May 25, 2020·International Journal of Clinical Oncology·Kyoko ShimadaSatoshi Yamaguchi
Aug 3, 2021·Clinical Reviews in Allergy & Immunology·Lulu R TsaoMariana C Castells

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.